Ensoma Stock

www.ensoma.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $163.05MM

Ensoma, founded in 2019, is a biotechnology company with the goal of expanding the reach of the curative power of genomic medicine by seeking to pioneer a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies aim to be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. Ensoma is headquartered in Boston, Massachusetts.

Register To Buy and Sell Shares

For more details on financing and valuation for Ensoma, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Ensoma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Ensoma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Ensoma investors also invested in these private companies

Bill & Melinda Gates Foundation
RIT Capital Partners
Mirae Asset Global Investments
Arix Bioscience
Bioluminescence Ventures
Gilead Sciences
Solasta Ventures
5AM Ventures
Fred Hutchinson Cancer Research Center
Kite Pharma

Team

Management Team

Emile Nuwaysir Ph.D
Chief Executive Officer & President
Min Wang Ph.D
President & Chief Operating Officer
Daniel Leblanc
Chief Technology Officer
Robert Peters Ph.D
Chief Scientific Officer
Naina Bhasin Ph.D
Chief Business Officer
André Lieber Ph.D
Co-Founder & Scientific Advisor

Board Members

Kush Parmar Ph.D
5AM Ventures
Mark Chin
Arix Bioscience
Paula Soteropoulos
5AM Ventures
Stephen Knight MD
F-Prime Capital

Frequently Asked Questions About Ensoma’s Stock

plusminus
Can you buy Ensoma’s stock?
Ensoma is not publicly traded on NYSE or NASDAQ in the U.S. To buy Ensoma’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Ensoma’s stock?
Yes, you can sell stock of a private company like Ensoma. Forge can help you sell your Ensoma stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Ensoma’s stock price?
Ensoma is a privately held company and therefore does not have a public stock price. However, you may access Ensoma’s private market stock price with Forge Data.
plusminus
What is Ensoma’s stock ticker symbol?
Ensoma does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Kite Leads $50M Series B For Ensoma
Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million.
In vivo cell therapy technology advances with Ensoma’s Twelve Bio acquisition
The concept of in vivo cell therapies moves two steps ahead with the announcements that Ensoma raised $85 million in a series B financing round and added a Cas12a gene editing system to its toolbox through the acquisition of Twelve Bio.
Updated on: May 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.